Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insights into the human CD59 complement binding interface toward engineering new therapeutics.

Yuxiang Huang1, Colin A Smith, Hongbin Song

  • 1Department of Microbiology and Immunology, Medical University of South Carolina, South Carolina 29403, USA.

The Journal of Biological Chemistry
|August 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysregulation of complement at the synapse in P301S mice and human tauopathies.

Acta neuropathologica communications·2026
Same author

Restraining Interproton Angular and Distance Dynamics with KEnRef.

The journal of physical chemistry. B·2026
Same author

Deamidation and isomerization to elusive isoaspartate in a computationally designed miniprotein.

Protein science : a publication of the Protein Society·2026
Same author

Braess' Paradox in Enzyme Kinetics: Asymmetry from Population Balance without Direct Cooperativity.

Journal of chemical theory and computation·2026
Same author

Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long COVID.

Immunology·2026
Same author

Absence of complement terminal pathway activity in C6-deficient mice prolongs survival in a mouse model of severe malarial infection.

Immunobiology·2025
Same journal

Isotope-Edited ESEEM: A New Method for Probing Copper Binding Sites in Neurodegenerative Proteins.

The Journal of biological chemistry·2026
Same journal

Introduction to the Thematic Review Series on Intracellular Protein Degradation. The ubiquitous biology of intracellular protein degradation: a tribute to Alfred L. ("Fred") Goldberg.

The Journal of biological chemistry·2026
Same journal

Correction: Aromatic residue-rich amino-terminal segments of temporin L self-assemble into collagen-mimetic peptides with cell-adhesion properties.

The Journal of biological chemistry·2026
Same journal

YhbO is a DJ-1 family glyoxalase and α-oxoaldehyde hydratase that confers resistance to reactive carbonyl stress (112).

The Journal of biological chemistry·2026
Same journal

ARMH3 acts as a central scaffold at the Golgi/TGN through interactions with Arl5, GBF1, and PI4KB.

The Journal of biological chemistry·2026
Same journal

PAX8 controls proximal tubule epithelial identity and stress response through epigenetic modification of distal regulatory elements.

The Journal of biological chemistry·2026
See all related articles

CD59 regulates complement by inhibiting the membrane attack complex (MAC). Mutagenesis revealed a broader binding interface, with some mutations significantly enhancing CD59

Area of Science:

  • Immunology
  • Molecular Biology
  • Biochemistry

Background:

  • CD59 is a crucial regulator of the complement system's terminal pathway.
  • It prevents the formation of the cytolytic membrane attack complex (MAC or C5b-9).
  • Understanding CD59's structure and function is key to developing therapies for inflammatory conditions.

Purpose of the Study:

  • To identify the C8/C9 binding interface of CD59.
  • To investigate methods for enhancing CD59's complement inhibitory activity.
  • To develop improved CD59-based therapeutics.

Main Methods:

  • Scanning alanine mutagenesis of CD59 residues 16-57.
  • Creation of an improved NMR structural model for CD59.
  • Site-specific mutagenesis and preparation of soluble mutant proteins.

Related Experiment Videos

Main Results:

  • Identified a broader C8/C9 binding interface than previously known.
  • Discovered specific mutations that significantly enhance CD59 activity.
  • Developed soluble CD59 mutants with up to 3-fold increased complement inhibitory activity.

Conclusions:

  • The CD59 binding interface is more extensive than previously recognized.
  • Mutagenesis offers a viable strategy to enhance CD59's therapeutic potential.
  • Enhanced soluble CD59 proteins represent promising candidates for treating inflammatory diseases.